Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis

Psoriasis

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

J Eur Acad Dermatol Venereol.

Thaçi D, Körber A, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Duetting E, Kraehn-Senftleben G, Amon U, Augustin M

doi: 10.1111/jdv.15962.

Psoriasis

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB

doi: 10.1111/jdv.15258.

Psoriasis

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis

Br J Dermatol.

Diels J, Thilakarathne P, Cameron C, McElligott S, Schubert A, Puig L

doi: 10.1111/bjd.18634.

Psoriasis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

J Eur Acad Dermatol Venereol.

Pinter A, Hoffmann M, Reich K, Augustin M, Kaplan K, Gudjónsdóttir SD, Delvin T, Mrowietz U, CHANGE investigator group.

doi: 10.1111/jdv.16932.

Psoriasis

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Am J Clin Dermatol.

Syed YY

doi: 10.1007/s40257-017-0254-4.

Psoriasis

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

J Eur Acad Dermatol Venereol.

Sawyer LM, Cornic L, Levin LÅ, Gibbons C, Møller AH, Jemec GB

doi: 10.1111/jdv.15277.

Psoriasis

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Lancet.

Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K

doi: 10.1016/

Psoriasis

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)

Br J Dermatol.

Thaҫi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K

doi: 10.1111/bjd.18696.

PsoriasisFurther Publications Dermatology

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up

Br J Dermatol

Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C

doi: 10.1111/bjd.20595

Related content

Secukinumab is effective in treatment of moderate to severe plaque psoriasis: Real-life effectiveness and safety from the PROSPECT study

Certolizumab Pegol for the Treatment of Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Pooled Analysis of Week 16 Data from 3 Randomized Controlled Trials

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS Analysis

A phase 4, randomised, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE)

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naïve to systemic treatment: Results from a randomised, active comparator-controlled phase 3b trial (POLARIS)

Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up